Elanco (ELAN) board director receives 10,314 deferred stock units in annual grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Elanco Animal Health Inc. reported that a board director received an annual equity grant in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock-equivalent deferred units at a stated price of $0 as an equity award for non-employee members of the Board of Directors. Following this grant, the director beneficially owns 84,813 shares of Elanco common stock in direct form. These awards align the director’s compensation more closely with long-term shareholder value through stock-based incentives.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Herendeen Paul
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 10,314 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 84,813 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider equity transaction did ELAN report in this filing?
Elanco Animal Health Inc. reported that a board director received an annual equity award consisting of 10,314 deferred stock units of Elanco common stock on 11/28/2025.
What was the price of the Elanco (ELAN) deferred stock units granted?
The 10,314 deferred stock units of Elanco common stock were granted at a stated price of $0 as part of the director’s annual equity award.
Why did the Elanco (ELAN) director receive these deferred stock units?
The deferred stock units were granted as an annual equity award to non-employee members of Elanco’s Board of Directors, aligning a portion of their compensation with the company’s equity.
Is this Elanco (ELAN) insider transaction part of a 10b5-1 trading plan?
The form includes a checkbox for transactions made under a Rule 10b5-1(c) plan, but the excerpt does not indicate that this particular equity grant was made under such a plan.